Synergism of IL-2-stimulated splenocytes and Pentopstam enhances the killing of Leishmania donovani in vitro

Clinical Immunology and Immunopathology

Volumn 81, Issue 1, 1996, Pages 74-81

  Eslami, Zohreh ^a   Gaucher, Denis ^a   Tanner, Charles E ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0030271361     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0160     Document Type: Article

References (19)

1. 1. Olivier, M., and Tanner, C. E., The effect of cyclosporin A in murine visceral leishmaniasis. Trop. Med. Parasitol. 40, 32-38, 1989.
2. 2. Vidal, S. M., Malo, D., Vogan K., Skamene, E., and Gros, P., Natural resistance to infection with intracellular parasites: Isolation of a candidate for Beg. Cell 73, 469-485, 1993.
3. 3. Berman, J. D., Waddell, D., and Hanson, B. D., Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Agents Chemother. 27, 916-920, 1985.
4. 4. Walsh, J. A., and Warren, K. S., Selective primary health care: An interim strategy for disease control in developing countries. N. Engl. J. Med. 301, 967-974, 1979.
5. 5. Hicsonmez, G., Jama, H., and Ozsoylu, S., Severe leucopenia during treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 82, 417, 1988.
6. 6. Napier, L. E., Sengupta, P. C., and Sen, G. N., The treatment of kala-azar by diamidinostilbene: Analysis of 101 cases. Ind. Med. Gaz. 77, 321-338, 1942.
7. 7. Sengupta, P. C., Chemotherapy of leishmanial disease: A resume of recent researches. Ind. Med. Gaz. 88, 20-35, 1953.
8. 8. Bryceson, A. D. M., Chulay, J. D., Ho, M., Mugambii, M., Were, J. B., Muigai, R., Chunge, C., Gachihi, G., Meme, J., Anabwani, G., and Bhatt, S. M., Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans. R. Soc. Trop. Med. Hyg. 79, 700-704, 1985.
9. 9. Berman, J. D., Chulay, J. D., Hendricks, L. D., and Oster, C. N., Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am. J. Trop. Med. Hyg. 31, 459-465, 1982.
10. 10. Berman, J. D., and Wyler, D. J., An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142, 83-86, 1980.
11. 11. Eslami, Z., and Tanner, C. E., Time course and intensity of infection in vitro in the resident peritoneal macrophages of resistant and susceptible mice exposed to different doses of Leishmania donovani promastigotes. Int. J. Parasitol. 24, 743-747, 1994.
12. 12. Eslami, Z., Olivier, M., and Tanner, C. E., Immunotherapy with IL-2-stimulated splenocytes reduces in vitro the level of Leishmania donovani infection in peritoneal macrophages. Int. J. Parasitol. 25, 975-981, 1995.
13. 13. Olivier, M., Eslami, Z., and Tanner, C. E., IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo. J. Parasitol. 82, 78-81, 1996.
14. 14. Mishell, B. B., and Shiigi, S. M., "Selected Methods in Cellular Immunology." W. H. Freeman and Company, San Francisco, 1980.
15. 15. Negre, E., Chance, M. L., Hanboula, S. Y., Monsigny, M., Roche, A-C., Mayer, R. M., and Hommel, M., Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins. Antimicrob. Agents Chemother. 36, 2228-2232, 1992.
16. 16. Nickol, A. D., and Bonventre, P. F., Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: Immunosuppression by adherent spleen cells. Infect. Immun. 50, 160-168, 1985.
17. 17. Kuo, J., Fox, E., and McDonald, S., "SigmaStat: Statistical Software for Working Scientists; A User's Manual," pp. 6.67-6.78. Jandel Scientific, San Rafael, CA, 1992.
18. 18. Murray, H. W., Stern, J. J., Weite, K., Rubin, B. Y., Carriero, S. M., and Nathan, C. F., Experimental visceral leishmaniasis: Production of interleukin 2 and interferon-gamma, tissue immune reaction and response to treatment with interleukin 2 and Interferon-gamma. J. Immunol. 138, 2290-2297, 1987.
19. 19. Olivier, M., Bertrand, S., and Tanner, C. E., Killing of Leishmania donovani by activated liver macrophages from resistant and susceptible strains of mice. Int. J. Parasitol. 19, 377-383, 1989.